Cargando…

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

BACKGROUND: To date, no good marker for screening or disease monitoring of endometrial cancer (EC) is available. The aims of this study were to investigate HE4 gene, protein expression and serum HE4 (sHE4) levels in a panel of ECs and normal endometria (NEs) and to correlate sHE4 with patient clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bignotti, E, Ragnoli, M, Zanotti, L, Calza, S, Falchetti, M, Lonardi, S, Bergamelli, S, Bandiera, E, Tassi, R A, Romani, C, Todeschini, P, Odicino, F E, Facchetti, F, Pecorelli, S, Ravaggi, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101927/ https://www.ncbi.nlm.nih.gov/pubmed/21468050 http://dx.doi.org/10.1038/bjc.2011.109

Ejemplares similares

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
por: Bignotti, E, et al.
Publicado: (2008)

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma
por: Bignotti, Eliana, et al.
Publicado: (2012)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues
por: Romani, Chiara, et al.
Publicado: (2014)

Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients
por: Bignotti, Eliana, et al.
Publicado: (2020)

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
por: Tassi, Renata A, et al.
Publicado: (2009)

Identification of stably expressed reference small non‐coding RNAs for microRNA quantification in high‐grade serous ovarian carcinoma tissues
por: Bignotti, Eliana, et al.
Publicado: (2016)

RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients
por: Vezzoli, Marika, et al.
Publicado: (2017)

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines
por: Bandiera, Elisabetta, et al.
Publicado: (2016)

L1CAM expression as a predictor of platinum response in high‐risk endometrial carcinoma
por: Romani, Chiara, et al.
Publicado: (2022)

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery
por: Romani, Chiara, et al.
Publicado: (2015)

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis
por: Zanotti, Laura, et al.
Publicado: (2017)

The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features
por: Romani, Chiara, et al.
Publicado: (2021)

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis
por: Bignotti, Eliana, et al.
Publicado: (2013)

Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma
por: Ravaggi, Antonella, et al.
Publicado: (2022)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
por: Romani, Chiara, et al.
Publicado: (2020)

VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients
por: Ravaggi, Antonella, et al.
Publicado: (2022)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2019)

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2017)

Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis
por: Yamamoto, E, et al.
Publicado: (2007)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival
por: Kamal, A M, et al.
Publicado: (2016)

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
por: Ino, K, et al.
Publicado: (2006)

Infrared spectroscopy with multivariate analysis to interrogate endometrial tissue: a novel and objective diagnostic approach
por: Taylor, S E, et al.
Publicado: (2011)

Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer
por: Bandiera, Elisabetta, et al.
Publicado: (2012)

Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial
por: Seebacher, V, et al.
Publicado: (2012)

Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer
por: Voss, M A, et al.
Publicado: (2011)

Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer
por: Leung, W K, et al.
Publicado: (2005)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

Impact of genomic stability on protein expression in endometrioid endometrial cancer
por: Lomnytska, M I, et al.
Publicado: (2012)

A clinically applicable molecular-based classification for endometrial cancers
por: Talhouk, A, et al.
Publicado: (2015)

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
por: Versluis, M A, et al.
Publicado: (2015)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
por: Shoji, K, et al.
Publicado: (2009)

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
por: van der Putten, Louis JM, et al.
Publicado: (2016)

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients
por: Felix, A S, et al.
Publicado: (2012)

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer
por: Mori, N, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_l6amv10dd7th16i5ldbb6omfff